Endotelix is providing solutions for Antiphospholipid Syndrome, including diagnostic tests and therapies.
Endotelix has raised $100K in total funding. The most recent round was Debt Financing. The last funding was announced in March 2023.
Endotelix's investors include Venture Kick, FONGIT Innovation Fund.
Endotelix is headquartered in Plan-les-ouates, Switzerland.
Endotelix is providing solutions for Antiphospholipid Syndrome, including diagnostic tests and therapies.
Endotelix is at the Debt Financing stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Endotelix — Funding & Investors." VCBacked, March 16, 2023, https://www.vcbacked.co/company/endotelix. Accessed September 30, 2026.
VCBacked. (2023). Endotelix — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/endotelix
{{cite web |title=Endotelix — Funding & Investors |url=https://www.vcbacked.co/company/endotelix |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated